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Keywords: Cystic ﬁbrosis; Chicken poxVaricella zoster virus (VZV) infection can result in
significant morbidity in patients with cystic fibrosis (CF), and
the risk of severe pulmonary complications rises with age [1].
This is a greater concern in those receiving systemic
corticosteroids, which in the case of CF is most often given
for acute allergic bronchopulmonary aspergillosis (ABPA).
Severe complications such as pneumonitis, secondary bacterial
infections, and liver failure may occur despite prompt
treatment with antiviral agents. The seroprevalence of VZV
antibodies in CF children is unknown, although in the general
population N80% of children over 6 years of age have
evidence of immunity [2]. We aimed to investigate the
seroprevalence of VZV antibodies in children attending our320 CF patients in clinic
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Fig. 1. Results of VZV antibody testing in
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history of chicken pox.
In 2011 we started routine testing for VZV antibodies in
6 year olds at their annual review. This age was selected in view
of the low prevalence of ABPA under that age and the chance that
children would already have had chicken pox. Evidence of
immunity to VZV was determined by VZV IgG antibodies
≥0.9 IU/L (measured by a VIDAS VZV IgG enzyme-linked
fluorescent immunoassay). In 2012 the prevalence of ABPA in
our CF clinic was 9%, 96% of which was aged 6 and above. As
this was a new policy, we also tested older children in order to
cover the whole clinic. We identified all children in our CF
clinic aged ≥6 years at August 2012, and collected data on=178
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• 19 offered vaccine
• 2 developed chicken pox
• 1 deceased
CF children aged 6 years and above.
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354 Letter to the EditorVZV immunity 12 months later, thus ensuring that children
aged ≥6 years at the initial time-point would have had an
annual review. We asked general practitioners to vaccinate
patients with a negative result.
There were 232 patients aged≥6 years. 178 patients (77%)
in this cohort had been tested for evidence of VZV immunity
within the year. Of these, n = 22 (12%) had no evidence of
VZV antibodies and were therefore susceptible to chickenpox
(Fig. 1).
In our paediatric CF population, the prevalence of VZV
antibodies was similar to that reported for the general
population. However, unlike the general population, children
with CF are at greater risk of serious complications from
varicella infection. In contrast to other groups of patients with
chronic diseases whose treatment may result in immunosup-
pression, there is no UK-wide specific recommendation forVZV immunization in CF. Vaccination against VZV before
immune compromise has been used as a strategy to prevent
VZV complications in patients starting immunosuppressive
therapy [3]. We suggest screening for VZV antibodies in
children with CF at 6 years and offering vaccination for those
found to be seronegative.References
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